The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Open accessAbstract
Purpose: Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared the efficacy of olaparib plus paclitaxel (olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric cancer and assessed whether low ATM expression is predictive of improved clinical outcome for olaparib/paclitaxel. Patients and Methods: In this phase II, double-blind study (Study 39; NCT01063517), patients were randomly assigned to oral olaparib 100 mg twice per day (tablets) plus paclitaxel (80 mg/m 2 per day intravenously on days 1, 8, and 15 of every 28-day cycle) or placebo plus paclitaxel (placebo/paclitaxel), followed by maintenance monotherapy with olaparib (200 mg twice per day) or placebo. The study population was enriched to 50% for patients with low or undetectable ATM levels (ATM low). Primary end point was progression-free survival (PFS). Results: One hundred twenty-three of 124 randomly assigned patients received treatment (olaparib/paclitaxel, n = 61; placebo/paclitaxel, n = 62). The screening prevalence of ATM low patients was 14%. Olaparib/paclitaxel did not lead to a significant improvement in PFS versus placebo/paclitaxel (overall population: hazard ratio [HR], 0.80; median PFS, 3.91 v 3.55 months, respectively; ATM low population: HR, 0.74; median PFS, 5.29 v 3.68 months, respectively). However, olaparib/paclitaxel significantly improved overall survival (OS) versus placebo/paclitaxel in both the overall population (HR, 0.56; 80% CI, 0.41 to 0.75; P = .005; median OS, 13.1 v 8.3 months, respectively) and the ATM low population (HR, 0.35; 80% CI, 0.22 to 0.56; P = .002; median OS, not reached v 8.2 months, respectively). Olaparib/paclitaxel was generally well tolerated, with no unexpected safety findings. Conclusion: Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATM low patients. A phase III trial in this setting is under way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationMcCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationGelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5805 · Cited by 541
DNA damage-induced activation of ATM and ATM-dependent signaling pathways
Kurz, E. U., & Lees-Miller, S. P. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.029 · Cited by 478
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011
Jung, K.-W., Won, Y.-J., Kong, H.-J., Oh, C.-M., Lee, D. H., & Lee, J. S. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.2.109 · Cited by 357
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193
Self-citationDent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184
Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 158
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Min, A., Im, S., Yoon, Y., Song, S., Nam, H.-J., Hur, H.-S., Kim, H., Lee, K.-H., Han, S., Oh, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0950 · Cited by 146
Self-citationKubota, E., Williamson, C. T., Ye, R., Elegbede, A. A., Peterson, L., Lees‐Miller, S. P., & Bebb, D. G. (2014) · Cell Cycle · doi:10.4161/cc.29212 · Cited by 131
The Heterochromatic Barrier to DNA Double Strand Break Repair: How to Get the Entry Visa
Goodarzi, A. A., & Jeggo, P. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911844 · Cited by 125
Khan, O., Gore, M. E., Lorigan, P. C., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A. J., McGown, G., Thorncroft, M. R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.8 · Cited by 123
Paclitaxel chemotherapy for the treatment of gastric cancer
Sakamoto, J., Matsui, T., & Kodera, Y. (2009) · Gastric Cancer · doi:10.1007/s10120-009-0505-z · Cited by 106
Kodera, Y., Ito, S., Mochizuki, Y., Fujitake, S., Koshikawa, K., Kanyama, Y., Matsui, T., Kojima, H., Takase, T., Ohashi, N., et al. (2007) · PubMed · Cited by 99
Kim, H., Saka, B., Knight, S., Borges, M. W., Childs, E. J., Klein, A. P., Wolfgang, C. L., Herman, J. M., Adsay, V. N., Hruban, R. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1239 · Cited by 91
Paolettí, X., Oba, K., Bang, Y., Bleiberg, H., Boku, N., Bouché, O., Catalano, P. J., Fuse, N., Michiels, S., Moehler, M. H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt269 · Cited by 90
Self-citationMatulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014) · Cancer · doi:10.1002/cncr.29082 · Cited by 87
Management of advanced gastric cancer
Price, T. J., Shapiro, J. D., Segelov, E., Karapetis, C. S., Pavlakis, N., Cutsem, E. V., Shah, M. A., Kang, Y., & Tebbutt, N. C. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.103 · Cited by 78
Randomized Phase II Trials: What Does Randomization Gain?
Wieand, H. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.956 · Cited by 59
Kim, H. S., Kim, M. A., Hodgson, D., Harbron, C., Wellings, R. P., O’Connor, M. J., Womack, C., Yin, X., Bang, Y., Im, S.-A., et al. (2013) · Pathobiology · doi:10.1159/000346034 · Cited by 57
Self-citationKim, J. W., Im, S., Kim, M. A., Cho, H. J., Lee, D. W., Lee, K., Kim, T., Han, S., Oh, D., Lee, H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28245 · Cited by 50
Self-citationGiaccone, G., Rajan, A., Kelly, R. J., Gutierrez, M. E., Kummar, S., Yancey, M. F., Ji, J., Zhang, Y., Parchment, R. E., & Doroshow, J. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3027 · Cited by 37
van der Noll, R., Ang, J. E., Jager, A., Marchetti, S., Mergui‐Roelvink, M., Bono, J. S. D., Lolkema, M. P., Brunetto, A. T., Arkenau, H., Jonge, M. J. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2579 · Cited by 34
Mateo, J., Hall, E., Sandhu, S. K., Omlin, A. G., Miranda, S., Carreira, S., GOODALL, J. C., Gillman, A., Mossop, H., Ralph, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.20 · Cited by 15
Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib
Guo, X., Shen, D., Cheng, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b42 · Cited by 10
Cited by
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Self-citationState-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Li, H., Liu, Z.-Y., Wu, N., Chen, Y.-C., Cheng, Q., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01227-0 · Cited by 539
Metadata
- Authors
- Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., Fielding, A., Rowbottom, J., Hodgson, D., O'Connor, M. J., Yin, X., & Kim, W. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-20
- Volume
- 33
- Issue
- 33
- Pages
- 3858-3865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150878386
- Cited by
- 290
- References
- 36
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.